Search Results - "Valença, Loana"

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) by Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary‐Ellen, Sweeney, Cristopher J.

“…Background Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)…”
Get full text

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Nuzzo, Pier Vitale, Ravera, Francesco, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valença, Loana Bueno, El Zarif, Talal, Davidsohn, Matthew P., McClure, Heather, Oliveira, Thiago Martins, Vauchier, Charles, Pereira Mestre, Ricardo, Modesti, Mikol, Ravi, Praful, Patrikidou, Anna, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most…”
Get full text

Sequencing current therapies in the treatment of metastatic prostate cancer by Valenca, Loana B, Sweeney, Christopher J, Pomerantz, Mark M

“…Highlights • Development of several effective therapies has improved outcomes in prostate cancer. • Uncertainty remains regarding sequencing or combining of…”
Get full text

Non-clear cell renal cell carcinoma, part 2: therapy by Valenca, Loana B, Hirsch, Michelle S, Choueiri, Toni K, Harshman, Lauren C

“…Non-clear cell renal cell carcinomas (RCCs) represent a heterogeneous group of diseases with distinct molecular drivers, histologies, and clinical outcomes…”
Get full text

Non-clear cell renal cell carcinoma, part 1: histology by Valenca, Loana B, Hirsch, Michelle S, Choueiri, Toni K, Harshman, Lauren C

“…Non-clear cell renal cell carcinomas (RCCs) represent up to 20% of all RCCs. Despite often being clustered as a single entity, these tumors represent a…”
Get full text

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Nuzzo, Pier Vitale, Pederzoli, Filippo, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valenca Bueno, Loana, Andrade, Livia Maria Q S, Patrikidou, Anna, Mestre, Ricardo Pereira, Modesti, Mikol, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor…”
Get full text

Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study by Gennusa, Vincenzo, Saieva, Calogero, Lee-Ying, Richard M., Nuzzo, Pier Vitale, Spinelli, Gian Paolo, Zanardi, Elisa, Fotia, Giuseppe, Rossetti, Sabrina, Valenca, Loana Bueno, Patrikidou, Anna, Andrade, Livia, Pereira Mestre, Ricardo, Fornarini, Giuseppe, Procopio, Giuseppe, Santini, Daniele, Sweeney, Christopher, Heng, Daniel Yick Chin, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…166 Background: About 2/3 of all prostate cancer (PCa) deaths occur in patients aged ≥75, who are frequently diagnosed with advanced PCa. ARSi abiraterone…”
Get full text

Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study by Lee-Ying, Richard M., Saieva, Calogero, Nuzzo, Pier Vitale, Malgeri, Andrea, Fotia, Giuseppe, Zanardi, Elisa, Rossetti, Sabrina, Valenca, Loana Bueno, Patrikidou, Anna, Modesti, Mikol, Martins Oliveira, Thiago, Pignata, Sandro, Fornarini, Giuseppe, Procopio, Giuseppe, Santini, Daniele, Sweeney, Christopher, Heng, Daniel Yick Chin, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…107 Background: The optimal management of mCRPC in men aged ≥75 is challenging, and there is a paucity of clinical data in the literature. Although AA and E…”
Get full text

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer by Harshman, Lauren C, Wang, Xiaodong, Nakabayashi, Mari, Xie, Wanling, Valenca, Loana, Werner, Lillian, Yu, Yongjiang, Kantoff, Aaron M, Sweeney, Christopher J, Mucci, Lorelei A, Pomerantz, Mark, Lee, Gwo-Shu Mary, Kantoff, Philip W

“…Statin use has been associated with improved prostate cancer outcomes. Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate…”
Get more information

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study by Fotia, Giuseppe, Saieva, Calogero, Lee-Ying, Richard, Patrikidou, Anna, Nuzzo, Pier Vitale, Zanardi, Elisa, Rossetti, Sabrina, Davidsohn, Matthew, Eid, Marc, El Zarif, Talal, McClure, Heather, Spinelli, Gian Paolo, Damassi, Alessandra, Murianni, Veronica, Vauchier, Charles, Oliveira, Thiago Martins, Malgeri, Andrea, Modesti, Mikol, Mestre, Ricardo Pereira, Valenca, Loana, Ravi, Praful, Santini, Daniele, Pignata, Sandro, De Giorgi, Ugo, Sweeney, Christopher, Heng, Daniel, Procopio, Giuseppe, Russo, Antonio, Francini, Edoardo

“…Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged ≥ 75 is challenging due to limited data. Regardless of age, in real-world clinical…”
Get full text

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study by Patrikidou, Anna, Saieva, Calogero, Lee-Ying, Richard, Nuzzo, Pier Vitale, Zarif, Talal El, McClure, Heather, Davidsohn, Matthew, Eid, Marc, Spinelli, Gian Paolo, Catalano, Fabio, Cremante, Malvina, Fotia, Giuseppe, Rossetti, Sabrina, Valenca, Loana, Vauchier, Charles, Ottanelli, Carlotta, Andrade, Livia, Gennusa, Vincenzo, Mestre, Ricardo Pereira, Fornarini, Giuseppe, Pignata, Sandro, Procopio, Giuseppe, Santini, Daniele, Ravi, Praful, Sweeney, Christopher, Heng, Daniel, De Giorgi, Ugo, Fizazi, Karim, Russo, Antonio, Francini, Edoardo

“…Androgen receptor signalling inhibitors (ARSIs) abiraterone acetate (AA) enzalutamide (Enza), are currently the standard first-line (L1) treatments for…”
Get full text

Correlation between time to prostate cancer metastasis and overall survival after androgen-deprivation therapy initiation by Valenca, Loana Bueno, Werner, Lillian, Xie, Wanling, Nakabayashi, Mari, Kantoff, Philip W., Pomerantz, Mark M

“…Abstract only 250 Background: Currently,overall survival (OS) is used to determine treatment efficacy in trials for advanced prostate cancer (PC). Reliable…”
Get full text

Clinical outcomes of volume of disease on patients receiving enzalutamide abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Talal El Zarif, Matthew P. Davidsohn, Heather McClure, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Praful Ravi, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini

“…Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most…”
Get full text

Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer by Harshman, Lauren Christine, Nakabayashi, Mari, Xie, Wanling, Wang, Xiaodong, Valenca, Loana, Werner, Lillian, Mucci, Lorelei A., Lee, Gwo-Shu Mary, Sweeney, Christopher, Pomerantz, Mark, Kantoff, Philip W.

“…Abstract only 148 Background: Statin use has been associated with a decreased risk of recurrence after local therapy and a lower risk of prostate cancer…”
Get full text

Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC) by Albiges, Laurence, Xie, Wanling, Chen, Yu-Hui, Boher, Jean-Marie, Valenca, Loana Bueno, Bernard, Brandon David, Culine, Stephane, Habibian, Muriel, Carducci, Michael Anthony, DiPaola, Robert S., Liu, Glenn, Pomerantz, Mark, Nakabayashi, Mari, Kantoff, Philip W., Fizazi, Karim, Gravis, Gwenaelle, Sweeney, Christopher

“…Abstract only…”
Get full text

Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer by Harshman, Lauren Christine, Wang, Xiaodong, Nakabayashi, Mari, Xie, Wanling, Valenca, Loana Bueno, Werner, Lillian, Yu, Yongjiang, Kantoff, Aaron, Sweeney, Christopher, Mucci, Lorelei A., Pomerantz, Mark, Lee, Gwo-Shu Mary, Kantoff, Philip W.

“…Abstract only…”
Get full text